Product datasheet

Anti-BCL10 Antibody

Catalog Number: *PB0555*

BOSTER
antibody and ELISA experts
BOSTER BIOLOGICAL TECHNOLOGY
Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator,
East Lake High-Tech Development Zone, Wuhan.
Web: www.boster.com ***Phone:*** 027-67845390/1/2 ***Email:*** boster@boster.com

Basic Information

Product Name	Anti-BCL10 Antibody
Gene Name	BCL10
Source	Rabbit
Clonality	Polyclonal
Isotype	IgG
Species Reactivity	human
Tested Application	WB, IHC
Contents	500 ug/ml antibody with PBS, 0.02% NaN3, 1 mg/ml BSA and 50% glycerol.
Immunogen	A synthetic peptide corresponding to a sequence at the N-terminus of human Bcl10, identical to the related rat and mouse sequences.
Concentration	500 ug/ml
Purification	Immunogen affinity purified.
Observed MW	26 kDa
Dilution Ratios	Western blot (WB): 1:500-2000 Immunohistochemistry (IHC): 1:50-400 (Boiling the paraffin sections in 10mM citrate buffer,pH6.0,or PH8.0 EDTA repair liquid for 20 mins is required for the staining of formalin/paraffin sections.) Optimal working dilutions must be determined by end user.

Storage

12 months from date of receipt，-20℃ as supplied.

Background Information

BCL10, B-cell CLL/lymphoma 10, gene was identified by its translocation in a case of mucosa-associated lymphoid tissue(MALT) lymphoma. The BCL10 gene is mapped to chromosome 1p22. The protein encoded by this gene contains a caspase recruitment domain(CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are though to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are though to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process

BOSTER
antibody and ELISA experts
BOSTER BIOLOGICAL TECHNOLOGY
Building C21, 3rd to 5th Floors, Optics Valley Biopharmaceutical Accelerator,
East Lake High-Tech Development Zone, Wuhan.
Web: www.boster.com Phone: 027-67845390/1/2 Email: boster@boster.com

that leads to the malignancy.

Selected Validation Data



Western blot analysis of anti-BCL10 antibody (PB0555). The sample well of each lane was loaded with 30 ug of sample under reducing conditions.
Lane 1: human Raji whole cell lysates,
Lane 2: human Jurkat whole cell lysates,
Lane 3: human MCF-7 whole cell lysates,
Lane 4: human Hela whole cell lysates.
After electrophoresis, proteins were transferred to a membrane. Then the membrane was incubated with rabbit anti-BCL10 antigen affinity purified polyclonal antibody (PB0555) and probed with a goat anti-rabbit IgG-HRP secondary antibody (Catalog # BA1054). The signal is developed using ECL Plus Western Blotting Substrate (Catalog # AR1197). A specific band was detected for BCL10 at approximately 28 kDa. The expected band size for BCL10 is at 26 kDa.



IHC analysis of BCL10 using anti-BCL10 antibody (PB0555).
BCL10 was detected in a paraffin-embedded section of human lymph node carcinoma tissue. The tissue section was developed using HRP Conjugated Rabbit IgG Super Vision Assay Kit (Catalog # SV0002) with DAB (Catalog # AR1027) as the chromogen.